Review



primary human t lymphocytes  (Celprogen Inc)


Bioz Verified Symbol Celprogen Inc is a verified supplier
Bioz Manufacturer Symbol Celprogen Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 91
      Buy from Supplier

    Structured Review

    Celprogen Inc primary human t lymphocytes
    Suppression of tumorigenic behaviors of U2OS and MG63 OS cells by D-cAMP/cAMP- treated Jurkat cell-derived CM. CN = control, D-cAMP = Dibutyryl cAMP, CW = CW008, and CM = conditioned medium. The double asterisk indicates P < 0.01. (A, B) Suppression of MTT-based viability of U2OS and MG63 OS cells by D-cAMP-treated Jurkat cell-derived CM, respectively. (C – E) Suppression of MTT-based viability, EdU-based proliferation, and transwell invasion of U2OS cells by cAMP-treated Jurkat cell-derived CM. (F, G) Suppression of MTT-based viability of U2OS and MG63 OS cells by CW008-treated primary <t>human</t> <t>T</t> lymphocyte-derived serum-free CM, respectively.
    Primary Human T Lymphocytes, supplied by Celprogen Inc, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary human t lymphocytes/product/Celprogen Inc
    Average 91 stars, based on 1 article reviews
    primary human t lymphocytes - by Bioz Stars, 2026-02
    91/100 stars

    Images

    1) Product Images from "Suppression of osteosarcoma progression by engineered lymphocyte-derived proteomes"

    Article Title: Suppression of osteosarcoma progression by engineered lymphocyte-derived proteomes

    Journal: Genes & Diseases

    doi: 10.1016/j.gendis.2022.08.007

    Suppression of tumorigenic behaviors of U2OS and MG63 OS cells by D-cAMP/cAMP- treated Jurkat cell-derived CM. CN = control, D-cAMP = Dibutyryl cAMP, CW = CW008, and CM = conditioned medium. The double asterisk indicates P < 0.01. (A, B) Suppression of MTT-based viability of U2OS and MG63 OS cells by D-cAMP-treated Jurkat cell-derived CM, respectively. (C – E) Suppression of MTT-based viability, EdU-based proliferation, and transwell invasion of U2OS cells by cAMP-treated Jurkat cell-derived CM. (F, G) Suppression of MTT-based viability of U2OS and MG63 OS cells by CW008-treated primary human T lymphocyte-derived serum-free CM, respectively.
    Figure Legend Snippet: Suppression of tumorigenic behaviors of U2OS and MG63 OS cells by D-cAMP/cAMP- treated Jurkat cell-derived CM. CN = control, D-cAMP = Dibutyryl cAMP, CW = CW008, and CM = conditioned medium. The double asterisk indicates P < 0.01. (A, B) Suppression of MTT-based viability of U2OS and MG63 OS cells by D-cAMP-treated Jurkat cell-derived CM, respectively. (C – E) Suppression of MTT-based viability, EdU-based proliferation, and transwell invasion of U2OS cells by cAMP-treated Jurkat cell-derived CM. (F, G) Suppression of MTT-based viability of U2OS and MG63 OS cells by CW008-treated primary human T lymphocyte-derived serum-free CM, respectively.

    Techniques Used: Derivative Assay



    Similar Products

    primary human cd4 t lymphocytes  (Miltenyi Biotec)
    96
    Miltenyi Biotec primary human cd4 t lymphocytes
    Primary Human Cd4 T Lymphocytes, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary human cd4 t lymphocytes/product/Miltenyi Biotec
    Average 96 stars, based on 1 article reviews
    primary human cd4 t lymphocytes - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier
    primary human t lymphocytes  (Celprogen Inc)
    91
    Celprogen Inc primary human t lymphocytes
    Suppression of tumorigenic behaviors of U2OS and MG63 OS cells by D-cAMP/cAMP- treated Jurkat cell-derived CM. CN = control, D-cAMP = Dibutyryl cAMP, CW = CW008, and CM = conditioned medium. The double asterisk indicates P < 0.01. (A, B) Suppression of MTT-based viability of U2OS and MG63 OS cells by D-cAMP-treated Jurkat cell-derived CM, respectively. (C – E) Suppression of MTT-based viability, EdU-based proliferation, and transwell invasion of U2OS cells by cAMP-treated Jurkat cell-derived CM. (F, G) Suppression of MTT-based viability of U2OS and MG63 OS cells by CW008-treated primary <t>human</t> <t>T</t> lymphocyte-derived serum-free CM, respectively.
    Primary Human T Lymphocytes, supplied by Celprogen Inc, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary human t lymphocytes/product/Celprogen Inc
    Average 91 stars, based on 1 article reviews
    primary human t lymphocytes - by Bioz Stars, 2026-02
    91/100 stars
    		  Buy from Supplier
    primary human cd8 + cd45ra + naïve t lymphocytes  (STEMCELL Technologies Inc)
    90
    STEMCELL Technologies Inc primary human cd8 + cd45ra + naïve t lymphocytes
    Activation of <t>CD8</t> + T lymphocytes following antigenic presentation of various cell-penetrating peptides -conjugated MamA2.1 epitope. (A) Cytotoxicity of activated CD8 + T lymphocytes against human breast cancer cell lines, UACC812 (HLA-A2 + MamA + , demonstrated in grey) and MCF-7 (HLA-A2 + MamA - , demonstrated in crossed lines). (B and C) Gene expression of (B) IFNγ and (C) granzyme B in activated CD8 + T lymphocytes. * P<0.05, as compared with the unconjugated MamA2.1 epitope. MamA2.1, mammaglobin-A; IFNγ, interferon-γ.
    Primary Human Cd8 + Cd45ra + Naïve T Lymphocytes, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary human cd8 + cd45ra + naïve t lymphocytes/product/STEMCELL Technologies Inc
    Average 90 stars, based on 1 article reviews
    primary human cd8 + cd45ra + naïve t lymphocytes - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    primary human cd8+cd45ra+ naive t lymphocytes  (STEMCELL Technologies Inc)
    90
    STEMCELL Technologies Inc primary human cd8+cd45ra+ naive t lymphocytes
    Activation of <t>CD8</t> + T lymphocytes following antigenic presentation of various cell-penetrating peptides -conjugated MamA2.1 epitope. (A) Cytotoxicity of activated CD8 + T lymphocytes against human breast cancer cell lines, UACC812 (HLA-A2 + MamA + , demonstrated in grey) and MCF-7 (HLA-A2 + MamA - , demonstrated in crossed lines). (B and C) Gene expression of (B) IFNγ and (C) granzyme B in activated CD8 + T lymphocytes. * P<0.05, as compared with the unconjugated MamA2.1 epitope. MamA2.1, mammaglobin-A; IFNγ, interferon-γ.
    Primary Human Cd8+Cd45ra+ Naive T Lymphocytes, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary human cd8+cd45ra+ naive t lymphocytes/product/STEMCELL Technologies Inc
    Average 90 stars, based on 1 article reviews
    primary human cd8+cd45ra+ naive t lymphocytes - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    primary cryopreserved normal human peripheral blood cd3+ t lymphocytes  (AllCells LLC)
    90
    AllCells LLC primary cryopreserved normal human peripheral blood cd3+ t lymphocytes
    Activation of <t>CD8</t> + T lymphocytes following antigenic presentation of various cell-penetrating peptides -conjugated MamA2.1 epitope. (A) Cytotoxicity of activated CD8 + T lymphocytes against human breast cancer cell lines, UACC812 (HLA-A2 + MamA + , demonstrated in grey) and MCF-7 (HLA-A2 + MamA - , demonstrated in crossed lines). (B and C) Gene expression of (B) IFNγ and (C) granzyme B in activated CD8 + T lymphocytes. * P<0.05, as compared with the unconjugated MamA2.1 epitope. MamA2.1, mammaglobin-A; IFNγ, interferon-γ.
    Primary Cryopreserved Normal Human Peripheral Blood Cd3+ T Lymphocytes, supplied by AllCells LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary cryopreserved normal human peripheral blood cd3+ t lymphocytes/product/AllCells LLC
    Average 90 stars, based on 1 article reviews
    primary cryopreserved normal human peripheral blood cd3+ t lymphocytes - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    human primary hla a 0201pos cd8 t lymphocytes  (Miltenyi Biotec)
    99
    Miltenyi Biotec human primary hla a 0201pos cd8 t lymphocytes
    Activation of <t>CD8</t> + T lymphocytes following antigenic presentation of various cell-penetrating peptides -conjugated MamA2.1 epitope. (A) Cytotoxicity of activated CD8 + T lymphocytes against human breast cancer cell lines, UACC812 (HLA-A2 + MamA + , demonstrated in grey) and MCF-7 (HLA-A2 + MamA - , demonstrated in crossed lines). (B and C) Gene expression of (B) IFNγ and (C) granzyme B in activated CD8 + T lymphocytes. * P<0.05, as compared with the unconjugated MamA2.1 epitope. MamA2.1, mammaglobin-A; IFNγ, interferon-γ.
    Human Primary Hla A 0201pos Cd8 T Lymphocytes, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human primary hla a 0201pos cd8 t lymphocytes/product/Miltenyi Biotec
    Average 99 stars, based on 1 article reviews
    human primary hla a 0201pos cd8 t lymphocytes - by Bioz Stars, 2026-02
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    Suppression of tumorigenic behaviors of U2OS and MG63 OS cells by D-cAMP/cAMP- treated Jurkat cell-derived CM. CN = control, D-cAMP = Dibutyryl cAMP, CW = CW008, and CM = conditioned medium. The double asterisk indicates P < 0.01. (A, B) Suppression of MTT-based viability of U2OS and MG63 OS cells by D-cAMP-treated Jurkat cell-derived CM, respectively. (C – E) Suppression of MTT-based viability, EdU-based proliferation, and transwell invasion of U2OS cells by cAMP-treated Jurkat cell-derived CM. (F, G) Suppression of MTT-based viability of U2OS and MG63 OS cells by CW008-treated primary human T lymphocyte-derived serum-free CM, respectively.

    Journal: Genes & Diseases

    Article Title: Suppression of osteosarcoma progression by engineered lymphocyte-derived proteomes

    doi: 10.1016/j.gendis.2022.08.007

    Figure Lengend Snippet: Suppression of tumorigenic behaviors of U2OS and MG63 OS cells by D-cAMP/cAMP- treated Jurkat cell-derived CM. CN = control, D-cAMP = Dibutyryl cAMP, CW = CW008, and CM = conditioned medium. The double asterisk indicates P < 0.01. (A, B) Suppression of MTT-based viability of U2OS and MG63 OS cells by D-cAMP-treated Jurkat cell-derived CM, respectively. (C – E) Suppression of MTT-based viability, EdU-based proliferation, and transwell invasion of U2OS cells by cAMP-treated Jurkat cell-derived CM. (F, G) Suppression of MTT-based viability of U2OS and MG63 OS cells by CW008-treated primary human T lymphocyte-derived serum-free CM, respectively.

    Article Snippet: Primary human T lymphocytes (#33002-02, Celprogen, CA, USA) were cultured in CTS™ OpTmizer™ T-Cell Expansion SFM (#A3705001, Thermo Fisher Scientific, Waltham, MA, USA).

    Techniques: Derivative Assay

    Activation of CD8 + T lymphocytes following antigenic presentation of various cell-penetrating peptides -conjugated MamA2.1 epitope. (A) Cytotoxicity of activated CD8 + T lymphocytes against human breast cancer cell lines, UACC812 (HLA-A2 + MamA + , demonstrated in grey) and MCF-7 (HLA-A2 + MamA - , demonstrated in crossed lines). (B and C) Gene expression of (B) IFNγ and (C) granzyme B in activated CD8 + T lymphocytes. * P<0.05, as compared with the unconjugated MamA2.1 epitope. MamA2.1, mammaglobin-A; IFNγ, interferon-γ.

    Journal: Molecular and Clinical Oncology

    Article Title: Conjugation with S4 protein transduction domain enhances the immunogenicity of the peptide vaccine against breast cancer

    doi: 10.3892/mco.2024.2815

    Figure Lengend Snippet: Activation of CD8 + T lymphocytes following antigenic presentation of various cell-penetrating peptides -conjugated MamA2.1 epitope. (A) Cytotoxicity of activated CD8 + T lymphocytes against human breast cancer cell lines, UACC812 (HLA-A2 + MamA + , demonstrated in grey) and MCF-7 (HLA-A2 + MamA - , demonstrated in crossed lines). (B and C) Gene expression of (B) IFNγ and (C) granzyme B in activated CD8 + T lymphocytes. * P<0.05, as compared with the unconjugated MamA2.1 epitope. MamA2.1, mammaglobin-A; IFNγ, interferon-γ.

    Article Snippet: Pooled primary human CD8 + CD45RA + naïve T lymphocytes collected from healthy donors were obtained from StemCell Technologies (cat. no. 70030).

    Techniques: Activation Assay, Gene Expression

    The N-terminus of S4 peptide is conjugated to various HLA-A2 restricted MamA antigenic epitopes. (A) Median fluorescence channel shift mediated by HLA-A2 expression on the cell surface T2 cells following treatment with S4 peptide conjugated HLA-A2 restricted MamA epitopes. (B and C) Cytotoxicity of these various peptide-activated CD8 + T lymphocytes against human breast cancer cell lines, (B) UACC812 and (C) MCF-7. (D and E) Gene expression of (D) IFNγ and (E) granzyme B in these various peptide-activated CD8 + T lymphocytes. * P<0.05, for conjugated MamA antigenic epitope as compared with the respective unconjugated epitope; # P<0.05, for S4 conjugated MamA2.X (X=2-7) as compared with S4 conjugated MamA2.1 antigenic epitope. S4, shaker-potassium channel protein; HLA, human leukocyte antigen; MamA2.1, mammaglobin-A; IFNγ, interferon-γ.

    Journal: Molecular and Clinical Oncology

    Article Title: Conjugation with S4 protein transduction domain enhances the immunogenicity of the peptide vaccine against breast cancer

    doi: 10.3892/mco.2024.2815

    Figure Lengend Snippet: The N-terminus of S4 peptide is conjugated to various HLA-A2 restricted MamA antigenic epitopes. (A) Median fluorescence channel shift mediated by HLA-A2 expression on the cell surface T2 cells following treatment with S4 peptide conjugated HLA-A2 restricted MamA epitopes. (B and C) Cytotoxicity of these various peptide-activated CD8 + T lymphocytes against human breast cancer cell lines, (B) UACC812 and (C) MCF-7. (D and E) Gene expression of (D) IFNγ and (E) granzyme B in these various peptide-activated CD8 + T lymphocytes. * P<0.05, for conjugated MamA antigenic epitope as compared with the respective unconjugated epitope; # P<0.05, for S4 conjugated MamA2.X (X=2-7) as compared with S4 conjugated MamA2.1 antigenic epitope. S4, shaker-potassium channel protein; HLA, human leukocyte antigen; MamA2.1, mammaglobin-A; IFNγ, interferon-γ.

    Article Snippet: Pooled primary human CD8 + CD45RA + naïve T lymphocytes collected from healthy donors were obtained from StemCell Technologies (cat. no. 70030).

    Techniques: Fluorescence, Expressing, Gene Expression

    Comparison of MamA2.1 epitope conjugation to N-terminus versus C-terminus of S4 peptide. (A) Median fluorescence channel shift by HLA-A2 expression on the cell surface T2 cells following treatment with MamA2.1-S4 vs S4-MamA2.1 peptides. (B and C) Cytotoxicity of these CD8 + T lymphocytes individually activated by MamA2.1-S4 and S4-MamA2.1 against human breast cancer cell lines, (B) UACC812 and (C) MCF-7. (D and E) Gene expression of (D) IFNγ and (E) granzyme B in these activated CD8 + T lymphocytes. * P<0.05. MamA2.1, mammaglobin-A; S4, shaker-potassium channel protein; HLA, human leukocyte antigen; IFNγ, interferon-γ.

    Journal: Molecular and Clinical Oncology

    Article Title: Conjugation with S4 protein transduction domain enhances the immunogenicity of the peptide vaccine against breast cancer

    doi: 10.3892/mco.2024.2815

    Figure Lengend Snippet: Comparison of MamA2.1 epitope conjugation to N-terminus versus C-terminus of S4 peptide. (A) Median fluorescence channel shift by HLA-A2 expression on the cell surface T2 cells following treatment with MamA2.1-S4 vs S4-MamA2.1 peptides. (B and C) Cytotoxicity of these CD8 + T lymphocytes individually activated by MamA2.1-S4 and S4-MamA2.1 against human breast cancer cell lines, (B) UACC812 and (C) MCF-7. (D and E) Gene expression of (D) IFNγ and (E) granzyme B in these activated CD8 + T lymphocytes. * P<0.05. MamA2.1, mammaglobin-A; S4, shaker-potassium channel protein; HLA, human leukocyte antigen; IFNγ, interferon-γ.

    Article Snippet: Pooled primary human CD8 + CD45RA + naïve T lymphocytes collected from healthy donors were obtained from StemCell Technologies (cat. no. 70030).

    Techniques: Comparison, Conjugation Assay, Fluorescence, Expressing, Gene Expression